Key words
Lippia nodiflora
- Verbenaceae - phenylethanoid glycosides - flavonoids - HPLC - pharmacokinetic
AUC area under the curve (AUC)
CV coefficient of variation
LOD limit of detection
LOQ limit of quantification
PPC peak plasma concentration
r
2 coefficient of determination
SEM standard error of the mean
Introduction
Lippia nodiflora (L.) Michx., also known as Phyla nodiflora (L.) Greene [1 ]
[2 ], is a fast-growing creeping perennial medicinal herb belonging to the Verbenaceae
family [3 ]. It is commonly known as Frog Fruit and has been traditionally used for the treatment
of knee joint pain, lithiasis, diuresis, urinary disorders, and swelling [1 ]
[2 ]
[3 ]
[4 ]
[5 ]. The plant is rich in flavonoids [6 ]
[7 ]
[8 ]
[9 ], phenols [10 ], triterpenoids, and steroids [11 ]
[12 ]. Pharmacological studies have shown that the plant possesses a broad array of biological
properties, including anti-urolithiasis [13 ], antihypertensive [14 ], antioxidant [15 ], antitumor [16 ], and anti-inflammatory [17 ] activity. In addition, our previous study indicated that phenyethanoid glycosides
and flavonoids of L. nodiflora were promising xanthine oxidase inhibitors [18 ]. Two phenylethanoid glycosides, namely, arenarioside (1 ) and verbascoside (2 ), together with three flavonoids, namely, 6-hydroxyluteolin (3 ), 6-hydroxyluteolin-7-O -glycoside (4 ), and nodifloretin (5 ), isolated from L. nodiflora were shown to have an antihyperuricemic effect in potassium oxonate- and hypoxanthine-induced
hyperuricemic rats, with 3 being the most active [19 ].
Due to the promising uric acid-lowering benefit of the phenylethanoid glycosides and
flavonoids reported previously [18 ]
[19 ], the characterization of their bioavailability and pharmacokinetic properties is
important for their further development into phytopharmaceuticals. Hitherto, there
is no report on the pharmacokinetic data of those antihyperuricemic constituents,
except verbascoside. In addition, no analytical method has been developed for the
simultaneous determination of the bioavailability and pharmacokinetics of bioactive
compounds 1 –5 in rats. The only study found was on the pharmacokinetic of acteoside, also known
as verbascoside, from Plantago asiatica or Cistanche deserticola using liquid chromatography-mass spectrometry [20 ], liquid chromatography-tandem mass spectrometry [21 ]
[22 ], or liquid chromatography with amperometric detection [23 ]. Previously, we developed, validated, and applied an HPLC method for the phytochemical
analysis of the antihyperuricemic constituents 1 –5 in the plant samples [24 ]. In the present study, we aimed at the development of a simple and reliable HPLC
method with a UV detection method for the simultaneous determination and quantification
of the antihyperuricemic constituents 1 –5 in rat plasma and to apply the method in the pharmacokinetic study of those bioactive
compounds in rats after oral and intravenous administration.
Results and Discussion
In the present study, a simple and reliable HPLC method was developed and validated.
It uses UV detection and gradient elution with a mobile phase consisting of 0.1% aqueous
acetic acid (solvent A) and acetonitrile (solvent B) for the simultaneous determination
and quantification of the five antihyperuricemic constituents in rat plasma with a
total run time of approximately 38 min ([Fig. 1b ]). Solvent A was chosen as it minimized the peak tailing effect related to the dissociation
of the hydroxyl group of flavonoids compared to the acid-free solvent. Acid-containing
mobile phases are often used for flavonoid separation [25 ]
[31 ]
[32 ]
[33 ]
[29 ]. Since phenylethanoid glycosides and flavonoids exhibited two different sets of
UV maxima at 218 and 332 nm, and 282 and 346 nm, respectively, a wavelength of 340 nm
producing a high absorbance for both phenylethanoid glycosides and flavonoids was
selected for the HPLC-UV analysis.
Fig. 1 HPLC chromatogram from the analysis of arenarioside (1 ), verbascoside (2 ), 6-hydroxyluteolin (3 ), 6-hydroxyluteolin-7-O -glycoside (4 ), and nodifloretin (5 ). a Blank rat plasma. b Mixed standards (10 µg/mL each of 1 –5 ) isolated from L. nodiflora . c Rat plasma spiked with 1 –5 (5 µg/mL each). d Rat plasma 1 h after intravenous administration of the mixture of 1 –5 (2 mg/kg each of 1 –5 ).
The calibration curves for the bioactive compounds in rat plasma were linear over
the concentration range investigated with a mean slope (±standard error of mean) of
152.00±3.75, 233.38±1.25, 540.33±3.53, 627.10±5.05, and 267.93±5.31 for 1 , 2 , 3 , 4 , and 5 , respectively. In addition, the coefficient of determination for the calibration
curve of all five compounds was equal to or greater than 0.9996 ([Table 1 ]). The LOD value was 78.1 ng/mL for 3 and 39.1 ng/mL for the rest of the compounds at a signal-to-noise ratio of 3. On
the other hand, the LOQ value for 3 was 312.5 ng/mL, whilst for the rest of the compounds, it was 156.3 ng/mL at a signal-to-noise
ratio of 12. The recovery of bioactive compounds 1 –5 ranged from 89.37–100.92% ([Table 2 ]), implying that deproteinization of the plasma with methanol did not result in any
substantial loss of the chemical constituents. The accuracy values were between 97.95
and 105.81% for intraday analysis and between 96.48 and 101.13% for inter-day analysis.
Meanwhile, the corresponding precision values were ranged from 1.15–9.06% for intraday
analysis and ranged from 0.75–7.71% for inter-day analysis. Both accuracy and precision
values indicated that the developed method was reliable and reproducible for the simultaneous
determination of the five bioactive chemical constituents in rat plasma.
Table 1 Regression equations, correlation coefficients, linear ranges, and limits of detection
and quantification of the antihyperuricemic constituents (1 –5 ) of L. nodiflora .
Compound
Regression equation
r
2
Linear range (ng/mL)
LOD (ng/mL)
LOQ (ng/mL)
Arenarioside
y=152.00x − 20.39
0.9999
156.3–20000
39.1
156.3
Verbascoside
y=233.38x − 58.81
0.9997
156.3–20000
39.1
156.3
6-Hydroxyluteolin
y=540.33x − 371.64
0.9996
312.5–20000
78.1
312.5
6-Hydroxyluteolin-7-O -glycoside
y=627.10x − 130.44
0.9996
156.3–20000
39.1
156.3
Nodifloretin
y=267.93x+59.24
0.9996
156.3–20000
39.1
156.3
Table 2 Recovery and intraday and inter-day precision and accuracy values of the bioactive
compounds (1 –5 ) of L. nodiflora .
Concentration (ng/mL)
Recovery (n=3)
Intraday (n=6)
Inter-day (n=6)
Mean (%)
Mean (CV, %)
Accuracy (% of true value)
Precision (CV, %)
Accuracy (% of true value)
Precision (CV, %)
Arenarioside
156.3
89.37
7.43
99.77
8.09
99.68
4.66
625
92.53
3.50
100.82
4.98
98.58
6.67
2 500
93.88
3.61
99.14
4.26
96.48
4.06
5 000
96.27
5.24
101.79
2.08
99.42
3.92
10 000
95.19
4.20
105.81
3.32
101.13
2.48
20 000
96.27
4.81
99.45
2.35
100.20
2.22
Verbascoside
156.3
91.11
4.30
99.55
9.06
100.81
6.69
625
94.67
7.88
101.53
3.39
97.15
7.71
2 500
94.56
3.72
99.06
1.89
100.10
3.68
5 000
92.83
6.61
99.14
2.18
98.99
5.81
10 000
93.94
3.85
99.93
4.66
99.95
1.68
20 000
96.81
2.82
99.36
1.76
99.36
1.94
6-Hydroxyluteolin
312.5
97.33
6.57
98.95
5.10
98.96
4.84
625
91.79
6.42
100.73
5.08
99.64
5.93
2 500
90.57
4.78
100.93
1.53
99.71
1.47
5 000
92.66
6.14
98.53
3.86
100.27
5.71
10 000
90.00
2.67
100.91
2.71
99.57
2.70
20 000
92.73
3.85
99.44
3.70
99.99
2.50
6-Hydroxyluteolin-7-O -glycoside
156.3
97.47
1.43
99.91
2.15
99.21
2.55
625
100.92
4.55
99.43
3.81
100.53
5.48
2 500
96.66
2.24
102.27
2.06
100.70
2.70
5 000
92.06
3.14
100.30
1.78
99.30
1.84
10 000
95.41
1.11
98.94
1.37
99.11
1.42
20 000
97.26
2.13
100.27
1.15
99.67
0.75
Nodifloretin
156.3
94.38
3.11
99.82
4.10
99.75
4.15
625
93.99
5.51
100.44
4.71
100.84
4.96
2 500
91.70
2.85
101.18
4.40
99.48
3.76
5 000
94.02
2.90
103.54
1.66
99.35
5.89
10 000
93.54
6.62
97.95
5.05
99.95
2.29
20 000
92.58
3.44
102.63
3.07
99.12
1.70
The developed and validated HPLC method was then successfully applied to simultaneously
determine and quantify the 5 antihyperuricemic constituents in the plasma of rats.
Rats were administered, either orally (20 mg/kg each of 1 –5 ) or intravenously (2 mg/kg each of 1 –5 ), a mixture of 1 –5 , consisting of 1 , 2 , 3 , 4 , and 5 in a ratio of 1:1:1:1:1. The bioactive phenylethanoid glycosides and flavonoids were
unambiguously identified as 1 –5 in the rat plasma upon comparison of the retention times with those of their respective
standards, as shown in the [Fig. 1 ]. The chromatogram of blank rat plasma is shown in [Fig. 1a–c ] shows the chromatogram of rat plasma spiked with bioactive compounds 1 –5 at a concentration of 5 µg/mL each, whereas [Fig. 1d ] shows the chromatogram of rat plasma 1 h after intravenous administration of the
mixture of 1 –5 (2 mg/kg each of 1 –5 ).
([Fig. 2a, b ]) illustrates the mean plasma concentration-time profiles of phenylethanoid glycosides
and flavonoids after intravenous administration of the mixture of 1 –5 . Following intravenous administration, compounds 1 –5 showed a gradual decline in the plasma concentration starting from the highest concentration
at 0 h. Interestingly, the concentrations of phenylethanoid glycosides found in the
rat plasma after intravenous administration was higher than those of the flavonoids,
with 1 exhibiting the highest PPC value of 11.07±0.93 µg/mL, while 2 showed the second highest PPC value of 8.75±1.10 µg/mL, followed by 4 , 5 , and 3 with their corresponding PPC values of 8.12±0.45, 5.89±0.67, and 4.13±0.57 µg/mL,
respectively.
Fig. 2 Mean plasma concentration-time profiles of a phenylethanoid glycosides (1 and 2 ) and b flavonoids (3 –5 ) after intravenous administration of the mixture of 1 –5 (2 mg/kg each of 1 –5 ); mean±SEM, n=6.
([Fig. 3a, b ]) illustrates the mean plasma concentration-time profiles of phenylethanoid glycosides
and flavonoids after oral administration of the mixture of 1 –5 . Following oral administration, all five compounds showed a rapid rise, and reached
the maximal concentration in the rat plasma with a T
max ranging from 0.5–0.67 h, indicating that they were rapidly absorbed and entered the
blood circulation system. This finding was consistent with an earlier study where
a phenylethanoid glycoside, acteoside, was shown to reach its maximal concentration
in the rat plasma (0.1 µg/mL) within the first 30 min after oral administration [21 ]. It is important to note that 1 showed a distinctively higher concentration in the rat plasma than the rest of the
compounds after oral administration, with a PPC value of 8.46±0.62 µg/mL, whereas
compound 5 showed the lowest concentration in the rat plasma after oral administration with
a PPC value of 0.38±0.01 µg/mL. The oral administration profile pattern displayed
by 2 was very similar to that displayed by 3 , as indicated by their close mean maximum plasma concentration values.
Fig. 3 Mean plasma concentration-time profiles of a phenylethanoid glycosides (1 and 2 ) and b flavonoids (3 –5 ) after oral administration of the mixture of 1 –5 (20 mg/kg each of 1 –5 ); mean±SEM, n=6.
[Table 3 ] summarizes the pharmacokinetic parameters of the bioactive compounds 1 –5 in rat plasma after intravenous or oral administration of the mixture of 1 –5 , comprising 2 mg/kg each of 1 –5 or 20 mg/kg each of 1 –5 , respectively. Following intravenous administration, 3 exhibited the highest V
d value, implying that a greater amount of 3 was distributed into the tissue compartment compared to the other compounds. Remarkably,
4 exhibited the lowest mean clearance value, indicating that it has been cleared from
the body slower than the other compounds. With regards to this, 4 had the longest corresponding half-life and the largest AUC value, suggesting that
the tissue distributed compound 4 was retained in tissue compartment and eliminated
slowly, despite its relatively small volume of distribution value. Thus, while 1 , 2 , 3 , and 5 showed a gradual decline to 0 at 24 h, 4 did not decline to 0 and still could be detected even at 24 h after both oral and
intravenous administration.
Table 3 Pharmacokinetic parameters of the antihyperuricemic constituents (1 –5 ) in rat plasma after intravenous (2 mg/kg of each compound) or oral (20 mg/kg of
each compound) administration of the mixture of 1 –5 .
Parameters
1
2
3
4
5
Intravenous administration
AUC0-∞ (µg h/mL)
18.69±0.79
16.72±1.67
6.98±0.70
22.80±0.59
9.52±1.30
K
e (h− 1)
0.76±0.01
0.64±0.04
0.45±0.05
0.15±0.01
1.35±0.08
t
1/2 (h)
0.92±0.01
1.11±0.08
1.65±0.24
4.75±0.10
0.53±0.03
V
d (L/kg)
0.14±0.01
0.21±0.03
0.76±0.18
0.60±0.03
0.17±0.02
CL (L/kg h)
0.11±0.01
0.13±0.01
0.30±0.03
0.09±0.01
0.23±0.03
Oral administration
AUC0-∞ (µg h/mL)
9.76±1.65
3.51±0.19
4.17±0.05
7.13±0.44
0.89±0.02
C
max (µg/mL)
8.97±0.79
1.07±0.07
1.06±0.03
0.65±0.04
0.38±0.01
T
max (h)
0.67±0.11
0.67±0.11
0.50±0.01
0.58±0.08
0.50±0.01
Following oral administration, 1 showed the highest mean C
max and AUC values, despite having the largest molecular size compared to the other compounds.
In contrast, 5 exhibited the lowest mean C
max and AUC values, suggesting that its absorption after oral administration was incomplete.
In general, the plasma levels of all 5 compounds given orally were much lower than
those of the intravenous administration, even though their oral doses were 10 times
higher than their intravenous doses, indicating that their oral bioavailability was
low and incomplete. The low oral bioavailability might be due to the first-pass metabolism
reducing the concentration of the compound before it reaches the systemic circulation
[30 ]. Nevertheless, it is interesting to note that the most potent antihyperuricemic
constituent 3 has the highest estimated absolute oral bioavailability value of 5.97%, followed
by 1 , 4 , 2 , and 5 , with estimated absolute oral bioavailability values of 5.22, 3.13, 2.10, and 0.93%,
respectively.
In conclusion, the pharmacokinetic study unveiled that the oral bioavailability of
the bioactive compounds of L. nodiflora was low and need to be improved, thus, further study for the development of phenylethanoid
glycoside and flavonoid formulations to enhance their oral bioavailability is warranted.
Materials and Methods
Chemicals and reagents
Deionized water was prepared using a Maxima ultra-pure water purifier system purchased
from Elga. HPLC grade methanol and acetonitrile were purchased from Merck. Sephadex
LH-20 (No. 17–0090–02) was purchased from GE Healthcare. Sodium heparin was purchased
from Acros Organic. Acetic acid was purchased from Systerm ChemAR.
Isolation of bioactive compounds
Frog Fruit [L. nodiflora (L.) Michx.] plants were collected from Seremban, Negeri Sembilan, Malaysia. The
plant was authenticated by Dr. Rahmad Zakaria, a botanist of the Herbarium Unit, School
of Biological Sciences, University of Science Malaysia (Universiti Sains Malaysia).
A voucher specimen (No. 11594) was deposited at the same unit. The 5 antihyperuricemic
constituents, namely, arenarioside (1 ), verbascoside (2 ), 6-hydroxyluteolin (3 ), 6-hydroxyluteolin-7-O -glycoside (4 ), and nodifloretin (5 ) ([Fig. 4 ]), were isolated from the bioactive fraction of L. nodiflora following the protocol described previously [19 ] and were used as marker compounds for the method validation and quantification of
rat plasma samples. The purity of the compounds was determined using an Agilent 1120
Compact LC system equipped with a variable wavelength photometric detector and Agilent
EZ-Chrom Elite Compact Software (Agilent Technologies) [24 ]. The purities were found to be 97.71, 98.19, 96.25, 97.30, and 97.36% for 1 , 2 , 3 , 4 , and 5 , respectively.
Fig. 4 The chemical structures of antihyperuricemic phenylethanoid glycosides (1 and 2 ) and flavonoids (3 –5 ) isolated from L. nodiflora .
Instrumentation
The HPLC system consisted of an Agilent 1120 Compact LC system equipped with a variable
wavelength photometric detector set at a wavelength of 340 nm, and Agilent EZ-Chrom
Elite Compact Software (Agilent Technologies). An Inertsil ODS-3 (4.6 mm i.d.×250 mm,
GL Ssciences Inc.) column pre-connected with an Inertsil ODS-3 guard column (4.6 mm
i.d.×50 mm, GL Sciences Ins.) was used for the chromatographic separation. The mobile
phase consisting of 0.1% aqueous acetic acid (A) and acetonitrile (B) was delivered
with gradient elution at a flow rate of 1.0 mL/min at room temperature. The gradient
elution was programmed as follows: 0–25 min, 15% B; 25–30 min, 20% B; 30–35 min, 36%
B; 35–38 min, 15% B. This was followed by a 12-min equilibration period prior to the
injection of each sample [24 ].
Sample preparation
Frozen plasma samples were thawed at the room temperature. A plasma sample (100 µL)
was transferred into a 1.5-mL microcentrifuge tube and proteins were precipitated
by adding 100 µL of methanol. The mixture was vortexed for 1 min using an Autovortex
SA6 (Stuart Scientific) and then centrifuged at 7711×g using a Micro 12 centrifuge (Hanil Science Industrial) for 15 min. The supernatant
was transferred into a new microcentrifuge tube and 20 µL were used for injection.
Limit of detection, limit of quantification, and linearity
The calibration curves were constructed by plotting peak areas against the concentrations
of the analyte prepared at 312.5, 625, 2 500, 5 000, 10 000, and 20 000 ng/mL for
3 and 156.3, 625, 2 500, 5 000, 10 000, and 20 000 ng/mL for 1 , 2 , 4 and 5 . The linearity of the curves was evaluated by linear regression analysis and was
expressed as the r
2 . LOD and LOQ were determined by triplicate analysis of a series of successive twofold
dilutions of the stock solutions. The LOD was defined as the lowest concentration
that the analytical system can reliably differentiate from the background level and
was calculated based on a signal-to-noise ratio of 3:1. The LOQ was defined as the
lowest quantifiable concentration on the calibration curve and was calculated based
on a signal-to-noise ratio of 12:1 [24 ]
[31 ]
[32 ].
Method validation
The method was validated through intraday and inter-day analysis of precision and
accuracy according to the International Conference on Harmonisation guidelines [33 ]. The intraday accuracy and precision were determined for each compound by evaluating
six replicate measurements of each concentration on a single day, while the inter-day
accuracy and precision were determined by assessing measurements of each concentration
over 6 consecutive days [24 ]. The recovery of the direct extraction method using methanol was calculated by comparing
the peak area of the compounds after extraction with those of the compounds dissolved
in the methanol at a similar concentration [24 ]. Accuracy was expressed as a percentage of true value, while precision was expressed
as a CV [24 ].
Animals
Male Sprague-Dawley rats (260–300 g) were obtained from the Animal Research and Service
Centre of the University of Science Malaysia (Universiti Sains Malaysia) and were
kept in the animal transit room of the School of Pharmaceutical Sciences, University
of Science Malaysia (Universiti Sains Malaysia), Penang, Malaysia. They were maintained
on a 12-h light/dark cycle at a room temperature of 25° C and were allowed free access to standard food pellets and tap water. The animals
were acclimatized for 1 week prior to experimentation. The study protocol was approved
by the Animal Ethics Committee, University of Science Malaysia (Universiti Sains Malaysia),
Penang, Malaysia [USM/Animal Ethics Approval/2013/(89)(478)] and was in accordance
with institutional guidelines (Guideline for the Care and Used of Animals for Scientific
Purposes, USM) and international policies (Public Health Service Policy on Humane
Care and Use of Laboratory Animal, and Guide for the Care and Use of Laboratory Animals)
[34 ]
[35 ].
Pharmacokinetic study
The animals were divided into two groups of three each and the study was conducted
according to a two-way crossover study design. Food, but not water, was withheld overnight
prior to the experimentation. Group 1 (n=3) was intravenously injected with a mixture
comprising bioactive compounds 1 –5 (2 mg/kg of each compound), while group 2 (n=3) was orally administered with a mixture
consisting of bioactive compounds 1 –5 (20 mg/kg of each compound). After a washout period of 2 weeks, the animals from
group 1 were orally administered with a mixture of 1 –5 comprising 20 mg/kg each of 1 –5 , while those from group 2 were intravenously injected with another mixture of 1 –5 consisting of 2 mg/kg each of 1 –5 . For both routes of drug administration, the mixture of 1 –5 was prepared in 20% of Tween 20 aqueous solution. The volume for intravenous injection
and oral administration was 1 mL/kg and 5 mL/kg of body weight, respectively. The
animals were placed in animal restraining cage during blood collection and the blood
samples of 0.5 mL were collected by the tail nipping method into a sodium heparin-coated
microcentrifuge tube at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, and 24 h after
drug administration. The blood samples were centrifuged at 4 000×g for 15 min and the resulting plasma samples were kept frozen at −20° C prior to analysis [31 ].
Data analysis
The following pharmacokinetic parameters were calculated: The elimination rate constant
(K
e ) was calculated from the slope of plasma concentration versus time curve. The slope
of the curve was equal to K
e /2.303. The elimination half-life (t
1/2 ) was determined as 0.693/K
e , while the volume of distribution (V
d ) was estimated using the equation V
d =dose/K
e ×AUC0−∞ . The theoretical concentration at time zero (C
o ) was calculated as the intercept of the semilogarithmic concentration-time curve.
The area under the plasma concentration-time curve to infinity (AUC0−∞ ) was determined by combining the area from time zero to the last sampling time (AUC0−t ) with the area from the last sampling time to infinity (AUCt−∞ ), whereby the trapezoidal rule was applied. Total body clearance (CL) was estimated
from the relationship CL=dose/AUC0−∞ . Peak concentration (C
max ) and time to reach C
max (T
max ) following oral administration were obtained directly from the plasma concentration-time
plots. The absolute oral bioavailability (F ) was calculated as the ratio of the dose-normalized AUC (AUC/dose) after oral and
intravenous administration. The results are expressed as the mean±SEM.
Supporting Information
The 1 H- and 13 C-NMR, MS, UV, and IR data of 1 –5 are available as Supporting Information.